Table 1 Selected EWAS CpG sites for pretreatment, posttreatment, and gene–drug interactions (p value <1E-5 is considered statistical signifiance and italicized)
CpG site | Chr | Location | Genes | Pretreatment β1 (95% CI) | Posttreatment β1 + δ (95% CI) | Modification effect (95% CI) | p value (Pre-) | p value (Post-) | p value (Modif.) |
|---|---|---|---|---|---|---|---|---|---|
Significant effect modification sites | |||||||||
cg20015535 | 1 | 231,556,123 | EGLN1 | 1.30 (0.11, 2.49) | −3.1 (−4.77, −1.43) | − 4.4 (−6.17, − 2.63) | 3.31E-02 | 2.80E-04 | 1.49E-06 |
cg24870738 | 1 | 45,097,499 | RNF220 | −3.8 (−5.9, −1.70) | 2.23 (0.58, 3.88) | 6.03 (3.44, 8.62) | 4.40E-04 | 7.81E-03 | 6.90E-06 |
cg06891775 | 10 | 80,704,982 | LOC283050 | 2.13 (1.28, 2.98) | 0.52 (−0.29, 1.33) | −1.61 (−2.3, − 0.92) | 1.39E-06 | 2.10E-01 | 5.91E-06 |
cg00607630 | 16 | 9,030,093 | USP7 | 2.82 (1.61, 4.03) | 0.04 (−1.15, 1.23) | −2.78 (−3.97, −1.59) | 7.18E-06 | 9.53E-01 | 6.60E-06 |
Significant pre or post methylation sites | |||||||||
cg03725309 | 1 | 109,757,585 | SARS | −1.65 (−2.18, − 1.12) | − 1.28 (− 1.85, −0.71) | 0.37 (0.04, 0.7) | 3.00E-09 | 9.82E-06 | 2.50E-02 |
cg12556569 | 11 | 116,664,039 | APOA5 | 0.35 (0.23, 0.47) | 0.23 (0.08, 0.38) | −0.12 (−0.24, 0) | 3.11E-08 | 2.34E-03 | 4.56E-02 |
cg11376147 | 11 | 57,261,198 | SLC43A1 | −2.24 (−3.01, −1.47) | −1.46 (− 2.37, −0.55) | 0.78 (0, 1.56) | 2.46E-08 | 1.60E-03 | 5.20E-02 |
cg00574958 | 11 | 68,607,622 | CPT1A | −3.81 (−4.44, − 3.18) | − 3.55 (−4.26, −2.84) | 0.26 (−0.31, 0.83) | 2.12E-28 | 1.07E-22 | 3.65E-01 |
cg01082498 | 11 | 68,608,225 | CPT1A | −2.59 (−3.48, −1.7) | −2.38 (−3.39, − 1.37) | 0.21 (−0.66, 1.08) | 1.86E-08 | 3.83E-06 | 6.30E-01 |
cg17058475 | 11 | 68,607,737 | CPT1A | −2.31 (−2.84, −1.78) | −2.34 (− 2.94, − 1.74) | −0.04 (−0.45, 0.37) | 5.00E-16 | 1.91E-14 | 8.63E-01 |
cg06500161 | 21 | 43,656,587 | ABCG1 | 2.26 (1.45, 3.07) | 2.16 (1.21, 3.11) | −0.09 (−0.86, 0.68) | 7.55E-08 | 8.18E-06 | 8.16E-01 |